一项随机III期临床试验的患者报告结局:根治性子宫切除术及盆腔淋巴结清扫术后的中危I/IIA期宫颈癌患者辅助放疗与放化疗的比较(NRG/GOG-0263)
NRG/GOG-0263随机III期试验前瞻性评估辅助放化疗(RT+CIS)与放疗(RT)对中危I-IIA期宫颈癌根治术后患者生活质量和患者报告结局的影响。共316例随机合格患者(RT+CIS组158例,RT组158例),在基线、3周、7周和36周完成问卷。RT+CIS组在3周和7周时FACT-Cx TOI评分较RT组显著降低,至36周两组均恢复至基线且无显著差异。
要点
- RT+CIS组3周时FACT-Cx TOI评分较RT组低5.1分(97.5%CI:-8.6至-1.6;p=0.004)。
- RT+CIS组7周时FACT-Cx TOI评分较RT组低6.3分(97.5%CI:-10.2至-2.4;p=0.002)。
- 36周时两组生活质量均恢复至基线,组间无显著差异(p=0.386)。
核心结论
- 两组治疗后生活质量均下降,RT+CIS组短期下降更明显,至36周两组生活质量和其它患者报告结局均恢复至基线。
- 神经病变、胃肠道/泌尿生殖道症状和疼痛随时间在两组间无显著差异。
研究设计与样本
- 随机III期临床试验(NRG/GOG-0263)的前瞻性患者报告结局评估,纳入316例随机合格的中危I-IIA期宫颈癌根治性子宫切除术及盆腔淋巴结清扫术后患者(RT+CIS组158例,RT组158例)。
- 在基线、3周、7周和36周使用FACT-Cx TOI、FACT/GOG-Ntx-4、简明疼痛量表最痛条目和5项胃肠道/泌尿生殖道症状条目进行评估。
- 采用线性混合模型校正基线评分、治疗、年龄、体能状态和国家。
主要发现
- 问卷完成率在基线、3周、7周和36周分别为98%、90%、88%和81%。
- RT+CIS组3周时FACT-Cx TOI平均评分较RT组低5.1分(97.5%CI:-8.6至-1.6;p=0.004),7周时低6.3分(97.5%CI:-10.2至-2.4;p=0.002)。
- 36周时两组评分均恢复至基线,组间无显著差异(p=0.386)。
- 患者报告的神经病变评分(FACT/GOG-Ntx-4)在任何时间点组间均无显著差异(p=0.82)。
- 患者报告的胃肠道/泌尿生殖道症状和疼痛在两组3周时均加重,至36周恢复至基线。
关键数值与推荐
- RT+CIS组3周时FACT-Cx TOI评分较RT组低5.1分(97.5%CI:-8.6至-1.6;p=0.004)。
- RT+CIS组7周时FACT-Cx TOI评分较RT组低6.3分(97.5%CI:-10.2至-2.4;p=0.002)。
- 36周时FACT-Cx TOI组间差异无统计学意义(p=0.386)。
- FACT/GOG-Ntx-4评分组间差异无统计学意义(p=0.82)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To prospectively evaluate the impact of adjuvant chemoradiation (RT + CIS) versus radiation (RT) on quality of life (QOL) and patient-reported outcomes (PROs) among patients with intermediate-risk, stage I-IIA cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy. METHODS: Patients enrolled in GOG-0263 completed PRO/QOL assessments at baseline, 3, 7, and 36 weeks using the FACT-Cx Trial Outcome Index (FACT-Cx TOI), FACT/GOG-Neurotoxicity subscale (FACT/GOG-Ntx-4), the worst pain item from the Brief Pain Inventory (BPI), and five gastrointestinal/genitourinary (GI/GU) symptom items. Linear mixed models adjusted for baseline score, treatment, age, performance status, and country. RESULTS: Among 316 randomized eligible patients (RT + CIS: n = 158; RT: n = 158), questionnaire completion rates were 98 %, 90 %, 88 %, and 81 % at baseline, weeks 3, 7, and 36, respectively. Patients receiving RT + CIS reported a mean FACT-Cx TOI score 5.1 points lower than RT at 3 weeks (97.5 % CI: -8.6 to -1.6; p = 0.004) and 6.3 points lower at 7 weeks (97.5 % CI: -10.2 to -2.4; p = 0.002). By 36 weeks, scores had returned to baseline in both groups, with no significant difference (p = 0.386). Patient-reported neuropathy scores (FACT/GOG-Ntx-4) did not differ significantly between groups at any time point (p = 0.82). Patient-reported GI/GU symptoms and pain worsened at 3 weeks in both arms, followed by recovery to baseline by 36 weeks. CONCLUSION: QOL declined in both groups after treatment initiation, with greater short-term deterioration in the RT + CIS group. By 36 weeks, QOL and other PROs returned to baseline in both groups. Neuropathy, GI/GU symptoms, and pain showed no significant differences between treatment arms over time.
引用
- Chase DM, Huang HQ, Deng W, et al. Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263). Gynecol Oncol. 2025. PMID: 41056581. doi:10.1016/j.ygyno.2025.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。